- AmCad BioMed Corporation is dedicated to developing innovative Computer-Assisted Detection and Diagnosis (CAD) devices. The company has successfully developed and commercialized a series of the pioneering, first-in-the-world medical devices.

- AmCad's strong pipeline includes AmCAD-UT (FDA, CE Mark and TFDA, for thyroid nodules analysis), AmCAD-UV (CE Mark, for classifying pulsatile), AmCAD-US (CE Mark, for backscattered signals analysis), AmCAD-UO (for obstructive sleep apnea detection), AmCAD-CA (for cytopathology analysis) and iSONO accessory (revolutionizing ultrasound imaging).

The state-of-the-art pipeline aims for early detection and diagnosis of various types of cancers, such as thyroid cancers, breast cancers, etc., and diseases, including liver fibrosis and obstructive sleep apnea.

- AmCad's Blue Ocean Strategy for the CAD systems is to develop its own core-technology platforms by providing high value-added, state-of-the-art medical solutions targeting a wide variety of clinical applications and raising the global competition to a higher level. We are ready to make extensive contribution to the health and wellbeing of humankind.